Paroxysmal hemoglobinuria
Drug research and approvals for paroxysmal hemoglobinuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 29 studies of paroxysmal hemoglobinuria are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 29
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
- To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.NCT07760467 · Phase 1 · Zhuhai United Laboratories Co., Ltd. · starts Aug 26, 2026
- Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07470762 · Phase 1 / Phase 2 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · starts Feb 14, 2026
- A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsNCT07462780 · Phase 1 · Shenzhen Kangzhe Biotechnology Co., Ltd. · starts Mar 5, 2026
- Danicopan PMS in KoreaNCT07457151 · Not reported · AstraZeneca · starts Apr 10, 2026
- A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyNCT07416162 · Not reported · Novartis Pharmaceuticals · starts Jun 15, 2026
- A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT07256301 · Phase 1 · Shanghai Lanyi Therapeutics Co., Ltd. · starts Jan 3, 2024
- REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07229235 · Not reported · Novartis Pharmaceuticals · starts Jan 13, 2026
- A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B,…NCT07187401 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Feb 11, 2026
Approved 6
- EculizumabComplement C5 inhibitor
- RavulizumabComplement C5 inhibitor
- PegcetacoplanComplement C3 inhibitor
- IptacopanComplement factor B inhibitor
- DanicopanComplement factor D inhibitor
- CrovalimabComplement C5 inhibitor
Phase 1 or earlier 4
- ZilucoplanComplement C5 inhibitor
- PozelimabComplement C5 inhibitor
- CemdisiranComplement C5 mRNA RNAi inhibitor
- Vemircopan
How its trials ended
157 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 75% met their primary endpoint, 0% missed it and 25% stopped early.
- Ongoing5636%
- Completed, result not reported5535%
- Met its primary endpoint3019%
- Stopped: sponsor or business decision74%
- Status unknown64%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
- Stopped: other or unclear11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA